title: Neurobrucellosis developing unilateral oculomotor nerve paralysis.
abstract: Brucellosis is a zoonotic infectious disease that is common around the world. Its clinical course demonstrates great diversity as it can affect all organs and systems. However, the central nervous system is rarely affected in the pediatric population. Neurobrucellosis is most frequently observed with meningitis and has numerous complications, including meningocephalitis, myelitis, cranial nerve paralyses, radiculopathy, and neuropathy. Neurobrucellosis affects the second, third, sixth, seventh, and eighth cranial nerves. Involvement of the oculomotor nerves is a very rare complication in neurobrucellosis although several adult cases have been reported. In this article, we present the case of a 9-year-old girl who developed unilateral nerve paralysis as a secondary complication of neurobrucellosis and recovered without sequel after treatment. This case is notable because it is a very rare, the first within the pediatric population. Our article emphasizes that neurobrucellosis should be considered among the distinguishing diagnoses in every case that is admitted for nerve paralysis in regions where Brucella infection is endemic.
authors.affiliation: Department of Pediatric Neurology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey. dr.sedatisikay@mynet.com
authors.forename: Sedat
authors.initials: S
authors.lastname: Işıkay
authors.forename: Kutluhan
authors.initials: K
authors.lastname: Yılmaz
authors.forename: Akgün
authors.initials: A
authors.lastname: Ölmez
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002002:Brucella; D002006:Brucellosis / Q000150:complications* / Q000188:drug therapy; D002443:Ceftriaxone / Q000008:administration & dosage / Q000627:therapeutic use; D020806:Central Nervous System Bacterial Infections / Q000150:complications*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015840:Oculomotor Nerve Diseases / Q000209:etiology* / Q000382:microbiology; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D002443:Ceftriaxone; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D012293:Rifampin